The estimated Net Worth of Robert E. George is at least 35.2 千$ dollars as of 26 December 2023. Robert George owns over 14,493 units of Moleculin Biotech Inc stock worth over 35,184$ and over the last 8 years Robert sold MBRX stock worth over 0$.
Sign up
Robert George MBRX stock SEC Form 4 insiders trading
Robert has made over 2 trades of the Moleculin Biotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Robert bought 14,493 units of MBRX stock worth 10,000$ on 26 December 2023.
The largest trade Robert's ever made was buying 14,493 units of Moleculin Biotech Inc stock on 26 December 2023 worth over 10,000$. On average, Robert trades about 1,408 units every 221 days since 2016. As of 26 December 2023 Robert still owns at least 14,660 units of Moleculin Biotech Inc stock.
You can see the complete history of Robert George stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert George's mailing address?
Robert's mailing address filed with the SEC is C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007.
Insiders trading at Moleculin Biotech Inc
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over 340,000$ worth of Moleculin Biotech Inc stock and bought 433,338 units worth 371,310$ . The most active insiders traders include Walter V Klemp、John M Climaco、Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of 69,293$. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth 2,357$.
What does Moleculin Biotech Inc do?
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
What does Moleculin Biotech Inc's logo look like?
Complete history of Robert George stock trades at Moleculin Biotech Inc
Moleculin Biotech Inc executives and stock owners
Moleculin Biotech Inc executives and other stock owners filed with the SEC include:
-
Walter V. Klemp,
Founder, Chairman, Pres & CEO -
Jonathan P. Foster CPA,
Exec. VP & CFO -
Jonathan P. Foster,
Exec. VP & CFO -
Dr. Donald H. Picker Ph.D.,
Chief Scientific Officer -
Dr. Donald H. Picker,
Chief Scientific Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer of New Products -
Dr. John Paul Waymack M.D., Sc.D.,
Sr. Chief Medical Officer -
Louis Ploth Jr.,
Independent Advisor -
Jacqueline Northcut,
Consultant -
Dr. Sandra L. Silberman,
Chief Medical Officer of New Products -
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.,
Chief Medical Officer of Annamycin -
Dr. Waldemar Priebe Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Jacqueline Northcut,
Director -
Michael D Cannon,
Director -
Robert E. George,
Director -
John M Climaco,
Director -
Waldemar Priebe,
10% owner -
Donald H Picker,
Chief Science Officer -
Walter V Klemp,
CEO and President -
Elizabeth Cermak,
Director -
Joy Yan,
Director -
Jonathan P. Foster,
Chief Financial Officer